Cargando…

A Network Meta-Analysis to Compare Effectiveness of Baricitinib and Other Treatments in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate

BACKGROUND/OBJECTIVES: This article compares the effectiveness of baricitinib (BARI) 4 mg (oral, Janus kinase [JAK] 1/2 inhibitor) versus other targeted synthetic/biologic disease-modifying antirheumatic drugs, in combination with methotrexate (MTX), in moderate-to-severe rheumatoid arthritis patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fakhouri, Walid, Wang, Xiaofei, de La Torre, Inmaculada, Nicolay, Claudia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Columbia Data Analytics, LLC 2020
Materias:	Autoimmune Diseases
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299462/ https://www.ncbi.nlm.nih.gov/pubmed/32685594 http://dx.doi.org/10.36469/jheor.2020.12273

Ejemplares similares

Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response
por: Valli, Atte, et al.
Publicado: (2022)

Persistence with Early-Line Abatacept versus Tumor Necrosis Factor-Inhibitors for Rheumatoid Arthritis Complicated by Poor Prognostic Factors
por: Han, Xue, et al.
Publicado: (2021)

Biologic Cost per Effectively Treated Rheumatoid Arthritis Patient in a Large Managed Care Population: A Retrospective Cohort Study
por: Gu, Tao, et al.
Publicado: (2015)

Functional Analysis of a Complement Polymorphism (rs17611) Associated with Rheumatoid Arthritis
por: Giles, Joanna L., et al.
Publicado: (2015)

Inflammaging as a link between autoimmunity and cardiovascular disease: the case of rheumatoid arthritis
por: Santos-Moreno, Pedro, et al.
Publicado: (2021)

A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models
por: Cho, Somi, et al.
Publicado: (2022)

Rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren’s syndrome shared megakaryocyte expansion in peripheral blood
por: Wang, Yukai, et al.
Publicado: (2022)

Diagnostic markers and potential therapeutic agents for Sjögren’s syndrome screened through multiple machine learning and molecular docking
por: Zhou, Liqing, et al.
Publicado: (2023)

A novel monoclonal antibody with improved FcγR blocking ability demonstrated non-inferior efficacy compared to IVIG in cynomolgus monkey ITP model at considerably lower dose
por: Nakajima-Kato, Yuko, et al.
Publicado: (2022)

New pro-inflammatory cytokine IL-40 is produced by activated neutrophils and plays a role in the early stages of seropositive rheumatoid arthritis
por: Navrátilová, Adéla, et al.
Publicado: (2023)

Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey
por: Maurer, M., et al.
Publicado: (2018)

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
por: Keystone, Edward C, et al.
Publicado: (2015)

Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study
por: van der Heijde, Désirée, et al.
Publicado: (2018)

The longitudinal loss of islet autoantibody responses from diagnosis of type 1 diabetes occurs progressively over follow-up and is determined by low autoantibody titres, early-onset, and genetic variants
por: Williams, C L, et al.
Publicado: (2022)

Combination therapy of a TRPV2 agonist with a TNF inhibitor achieves sustained suppression of disease severity and reduced joint damage
por: Laragione, Teresina, et al.
Publicado: (2022)

CTLA4, SH2B3, and CLEC16A diversely affect the progression of early islet autoimmunity in relatives of Type 1 diabetes patients
por: Vandewalle, Julie, et al.
Publicado: (2023)

Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy
por: Leipe, Jan, et al.
Publicado: (2018)

Comparing the Fiscal Consequences of Controlled and Uncontrolled Osteoarthritis Pain Applying a UK Public Economic Perspective
por: Martins, Rui, et al.
Publicado: (2021)

Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis
por: Fakhouri, Walid, et al.
Publicado: (2021)

Loss of the Protein Tyrosine Phosphatase PTPN22 Reduces Mannan-Induced Autoimmune Arthritis in SKG Mice
por: Sood, Shatakshi, et al.
Publicado: (2016)

Metabolites and metabolic pathways associated with rheumatoid arthritis and systemic lupus erythematosus
por: Duarte-Delgado, Nancy P., et al.
Publicado: (2022)

Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain
por: Schlueter, Max, et al.
Publicado: (2019)

Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids
por: Hu, Yanhua, et al.
Publicado: (2018)

Real-World Assessment of Weight Change in People with HIV-1 After Initiating Integrase Strand Transfer Inhibitors or Protease Inhibitors
por: Chen, Yen-Wen, et al.
Publicado: (2020)

IgE autoantibodies in serum and skin of non‐bullous and bullous pemphigoid patients
por: Lamberts, A., et al.
Publicado: (2020)

Cost-effectiveness Analysis of Hypoallergenic Milk Formulas for the Management of Cow’s Milk Protein Allergy in the United Kingdom
por: Martins, Rui, et al.
Publicado: (2021)

Clinical and Cost Burden of Primary Sjögren’s Syndrome: Descriptive Analysis Using a US Administrative Claims Database
por: Perera, Sue, et al.
Publicado: (2018)

Complement C4 Copy Number Variation is Linked to SSA/Ro and SSB/La Autoantibodies in Systemic Inflammatory Autoimmune Diseases
por: Lundtoft, Christian, et al.
Publicado: (2022)

Managing Cow’s Milk Protein Allergy in Indonesia: A Cost-effectiveness Analysis of Hypoallergenic Milk Formulas from the Private Payers’ Perspective
por: Paquete, Ana Teresa, et al.
Publicado: (2022)

The Economic and Humanistic Burden of Pediatric-Onset Multiple Sclerosis
por: Greene, Nupur, et al.
Publicado: (2022)

Development of a Conceptual Model to Understand Disease Burden in Patients With Systemic Lupus Erythematosus and Organ Damage
por: Broderick, Lynne, et al.
Publicado: (2023)

A Retrospective Patient Chart Review and Survey in Patients with Cryopyrin-associated Periodic Syndromes Treated with Anakinra
por: Lachmann, Helen J., et al.
Publicado: (2013)

The Cost-effectiveness of Celecoxib versus Non-steroidal Anti-inflammatory Drugs plus Proton-pump Inhibitors for Treating Osteoarthritis in Algeria
por: Hammoumraoui, Nadir, et al.
Publicado: (2013)

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
por: Taylor, Peter C., et al.
Publicado: (2023)

Lymph node biopsy analysis reveals an altered immunoregulatory balance already during the at‐risk phase of autoantibody positive rheumatoid arthritis
por: Ramwadhdoebe, Tamara H., et al.
Publicado: (2016)

Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy
por: Taylor, Peter C., et al.
Publicado: (2022)

Granulocyte‐augmented chemokine production induced by type II collagen containing immune complexes is mediated via TLR4 in rheumatoid arthritis patients
por: Manivel, Vivek Anand, et al.
Publicado: (2016)

A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA
por: Wehler, Elizabeth, et al.
Publicado: (2019)

Direct oral anticoagulants versus vitamin K antagonists in patients with antiphospholipid syndrome: systematic review and meta-analysis
por: Koval, Nazariy, et al.
Publicado: (2021)

Correction to: A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA
por: Wehler, Elizabeth, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_uhnncas1ksvg11l4s36prc3lbs